Therapeutic solutions for neurodegeneration
There is currently no available treatment to slow down or stop diseases related to neurodegeneration. They affect tens of millions of persons worldwide.
Alzprotect designs and develops innovative therapeutic solutions for these diseases.

An exceptional therapeutic potential for the treatment of tauopathies – Progressive Supranuclear Palsy (PSP) and Alzheimer’s disease.
Novel mechanism of action and promising therapeutic effects, acting on all known markers of neurodegeneration:
Amyloid beta peptide, Tau protein, Neuroinflammation, Oxidative stress.
News
ALZPROTECT DEVELOPS AN INNOVATIVE TREATMENT AND EXPANDS ITS CLINICAL TRIALS, FOLLOWING VERY POSITIVE RESULT
Loos, september 21st 2023
World Alzheimer’s day 2023
ALZPROTECT DEVELOPS AN INNOVATIVE TREATMENT AND EXPANDS ITS CLINICAL TRIALS, FOLLOWING VERY POSITIVE RESULT
Alzprotect, a biopharmaceutical company based in Lille, is currently testing an innovative drug against a neurodegenerative disease closely related to Alzheimer's disease. The very good results obtained have allowed Alzprotect to extend the clinical trial of this treatment for 6 months, and to prepare a larger scale study. The m...
Alzprotect strengthens its management team with the appointment of Dr. Olivier Defert as Chief Operating Officer
Lille (France), on 6th March 2023, Alzprotect, a biotechnology company focused on developing treatments for neurodegenerative diseases, announced the appointment of Dr. Olivier Defert as Chief Operating Officer (COO). Dr. Defert brings over 20 years of experience in the biotech and pharmaceutical industries, having held leadership positions in several companies. He is a highly qualified medicinal chemist who has held leadership positions at BioVersys SAS and Tarsier Pharma, among others. He foun...